CD8A and neoplasm: Regarding hepatic adaptive immune cells, SCFAs particularly butyrate, can enhance the anti-tumor activity of CD8+ T cells through various mechanisms, including metabolic reprogramming, epigenetic regulation, and immune checkpoint modulation.